Indeed, different types of PRMT5 inhibitors have been developed for cancer treatment and are categorized into 5 distinct types: SAM‐competitive (JNJ64619178), substrate‐competitive (GSK3326595 and EPZ015666), MTA‐cooperative (AMG193 and TNG908), allosteric, and PRMT5‐adaptor protein‒protein interaction inhibitors.[53] Currently, almost all the PRMT5 inhibitors under development have been designed to inhibit PRMT5 methyltransferase activity or disrupt the interactions between PRMT5 and its target proteins. The gene discussed is PRMT5; the disease is cancer.